文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

蛋白质功能化与内在放射性标记的[169Yb]Yb2O3纳米籽源用于纳米级近距离放疗

Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-01-25

本研究合成内在放射性标记并经阿拉伯胶糖蛋白功能化的[169Yb]Yb2O3纳米籽源,在B16F10荷瘤C57BL/6小鼠中经瘤内注射后行SPECT/CT显像、放射自显影与生物分布研究;结果显示放射性纳米制剂在肿瘤内均匀分布并滞留,不同剂量均可显著抑制肿瘤生长,最佳疗效见于约27.8 MBq剂量,治疗组肿瘤组织可见有丝分裂细胞丢失,而肾、肺和肝组织形态未见明显损伤。

要点

  • 瘤内注射[169Yb]Yb2O3纳米籽源后SPECT/CT与放射自显影显示其在肿瘤内均匀分布并滞留。
  • 肿瘤回归研究中,不同剂量放射性纳米颗粒组肿瘤生长较对照组显著受阻,最佳疗效见于约27.8 MBq剂量。
  • 组织病理分析显示治疗组肿瘤组织有丝分裂细胞丢失,肾、肺和肝组织形态未见明显损伤。

核心结论

  • 这些结果使纳米级近距离放疗有望成为不可切除实体癌的临床实用治疗方式。

研究设计与样本

  • 研究通过核反应堆中子辐照富集(168Yb丰度15.2%)的Yb2O3靶材生产169Yb(半衰期32天),经放射化学转化为[169Yb]YbCl3后用于纳米颗粒合成。
  • 在阿拉伯胶糖蛋白介质中控制Yb3+离子水解,合成内在放射性标记的纳米颗粒。
  • 在B16F10荷瘤C57BL/6小鼠中经瘤内注射放射性纳米颗粒后,进行体内SPECT/CT显像、放射自显影和生物分布研究。
  • 在同一小鼠模型中进行系统的肿瘤回归研究和组织病理学分析,以验证治疗效果。

主要发现

  • 该纳米制剂为澄清溶液,具有高胶体稳定性和放射化学稳定性。
  • SPECT/CT显像和放射自显影研究显示,放射性纳米制剂在肿瘤块中均匀分布并滞留。
  • 在肿瘤回归研究中,不同剂量的放射性纳米颗粒组较对照组肿瘤生长显著受阻,最佳治疗效果见于约27.8 MBq剂量。
  • 组织病理学分析显示,治疗组肿瘤组织中有丝分裂细胞明显丢失,而肾、肺和肝组织形态未见明显损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Classical brachytherapy of solid malignant tumors is an invasive procedure which often results in an uneven dose distribution, while requiring surgical removal of sealed radioactive seed sources after a certain period of time. To circumvent these issues, we report the synthesis of intrinsically radiolabeled and gum Arabic glycoprotein functionalized [169Yb]Yb2O3 nanoseeds as a novel nanoscale brachytherapy agent, which could directly be administered via intratumoral injection for tumor therapy. METHODS: 169Yb (T½ = 32 days) was produced by neutron irradiation of enriched (15.2% in 168Yb) Yb2O3 target in a nuclear reactor, radiochemically converted to [169Yb]YbCl3 and used for nanoparticle (NP) synthesis. Intrinsically radiolabeled NP were synthesized by controlled hydrolysis of Yb3+ ions in gum Arabic glycoprotein medium. In vivo SPECT/CT imaging, autoradiography, and biodistribution studies were performed after intratumoral injection of radiolabeled NP in B16F10 tumor bearing C57BL/6 mice. Systematic tumor regression studies and histopathological analyses were performed to demonstrate therapeutic efficacy in the same mice model. RESULTS: The nanoformulation was a clear solution having high colloidal and radiochemical stability. Uniform distribution and retention of the radiolabeled nanoformulation in the tumor mass were observed via SPECT/CT imaging and autoradiography studies. In a tumor regression study, tumor growth was significantly arrested with different doses of radiolabeled NP compared to the control and the best treatment effect was observed with ~ 27.8 MBq dose. In histopathological analysis, loss of mitotic cells was apparent in tumor tissue of treated groups, whereas no significant damage in kidney, lungs, and liver tissue morphology was observed. CONCLUSIONS: These results hold promise for nanoscale brachytherapy to become a clinically practical treatment modality for unresectable solid cancers.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ghosh S, Patra S, Younis MH, et al. Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds. Eur J Nucl Med Mol Imaging. 2024. PMID: 38270686. doi:10.1007/s00259-024-06612-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。